OVERCOMING RESISTANCE TO NK-MEDIATED LYSIS IN ENZALUTAMIDE-RESISTANT PROSTATE CANCER CELLS

被引：0
|
作者：
Dahut, Madeline [1 ]
Fousek, Kristen [1 ]
Horn, Lucas [1 ]
Qin, Haiyan [1 ]
Schlom, Jeffrey [1 ]
Palena, Claudia [1 ]
机构：
[1] Natl Canc Inst, Bethesda, MD USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0909
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
909
引用
收藏
页码：A947 / A947
页数：1
相关论文
共 50 条
  • [41] BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
    Luk, Iris Sze Ue
    Shrestha, Raunak
    Xue, Hui
    Wang, Yuwei
    Zhang, Fang
    Lin, Dong
    Haegert, Anne
    Wu, Rebecca
    Dong, Xin
    Collins, Colin C.
    Zoubeidi, Amina
    Gleave, Martin E.
    Gout, Peter W.
    Wang, Yuzhuo
    CLINICAL CANCER RESEARCH, 2017, 23 (06) : 1542 - 1551
  • [42] Role of exosome secretion in the survival of enzalutamide-resistant prostate cancer cells: Syntaxin 6 as a novel therapeutic target
    Peak, Taylor C.
    Kasica, Nicole P.
    Panigrahi, Gati K.
    Patterson, Sierra L.
    Singh, Ravi
    Hemal, Ashok K.
    Bitting, Rhonda L.
    Deep, Gagan
    CANCER RESEARCH, 2017, 77
  • [43] Biomarker Analysis of Men With Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer Treated With Pembrolizumab
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 15 - 16
  • [44] COMBINED AKT AND MEK PATHWAY BLOCKADE IN PRECLINICAL MODELS OF ENZALUTAMIDE-RESISTANT PROSTATE CANCER
    Toren, Paul
    Kim, Soojin
    Zoubeidi, Amina
    JOURNAL OF UROLOGY, 2016, 195 (04): : E813 - E814
  • [45] Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer
    Csizmarik, Anita
    Keresztes, David
    Nagy, Nikolett
    Bracht, Thilo
    Sitek, Barbara
    Witzke, Kathrin
    Puhr, Martin
    Tornyi, Ilona
    Lazar, Jozsef
    Takacs, Laszlo
    Kramer, Gero
    Sevcenco, Sabina
    Maj-Hes, Agnieszka
    Juranyi, Zsolt
    Hadaschik, Boris
    Nyirady, Peter
    Szarvas, Tibor
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (08) : 1405 - 1419
  • [46] Is the Patient Actually Failing on Enzalutamide? A Case Report and Issues to Consider in Enzalutamide-Resistant Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer
    Papageorgiou, Georgios Ioannis
    Skouteris, Nikolaos
    Kosma, Aikaterini
    Markouizou, Athina
    Charalampakis, Nikolaos
    REVIEWS ON RECENT CLINICAL TRIALS, 2023, 18 (02) : 146 - 155
  • [47] Enzalutamide-resistant related lncRNA NONHSAT210528 promotes the proliferation and invasion of prostate cancer
    Ye, Chen
    Chen, Yuan-Gui
    Qin, Sheng-Fei
    Tang, Shou-Yan
    Li, Song
    Shi, Min-Feng
    Zhou, Tie
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2022, 11 (05) : 643 - 658
  • [48] Aspalathus linearis suppresses AKT signaling, c-Myc, AR and survival of enzalutamide-resistant prostate cancer cells
    Chihpin, Chuu
    Huang, Shihhan
    Muller, Christo
    Wang, Bijuan
    Chang, Kaihsiung
    CANCER SCIENCE, 2022, 113 : 1338 - 1338
  • [49] Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
    Lin, Hui-Ming
    Mak, Blossom
    Yeung, Nicole
    Huynh, Kevin
    Meikle, Thomas G.
    Mellett, Natalie A.
    Kwan, Edmond M.
    Fettke, Heidi
    Tran, Ben
    Davis, Ian D.
    Mahon, Kate L.
    Zhang, Alison
    Stockler, Martin R.
    Briscoe, Karen
    Marx, Gavin
    Crumbaker, Megan
    Stricker, Phillip D.
    Du, Pan
    Yu, Jianjun
    Jia, Shidong
    Scheinberg, Tahlia
    Fitzpatrick, Michael
    Bonnitcha, Paul
    Sullivan, David R.
    Joshua, Anthony M.
    Azad, Arun A.
    Butler, Lisa M.
    Meikle, Peter J.
    Horvath, Lisa G.
    EBIOMEDICINE, 2021, 72
  • [50] Aberrant tumor metabolism to enable glucocorticoid receptor takeover in enzalutamide-resistant prostate cancer.
    Sharifi, Nima
    Li, Jianneng
    Alyamani, Mohammad
    Zhang, Ao
    Chang, Kai-Hsiung
    Berk, Mike
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345